ReViral Drug Discovery for Respiratory Syncytial Virus (RSV)

ReViral is a UK-based biotechnology company with a portfolio of drugs to treat Respiratory Syncytial Virus (RSV) infection. RSV currently represents a major unmet medical need in children, the elderly and the immunocompromised.

Our most advanced programme, RV521, is a highly potent, orally-administered inhibitor of RSV fusion protein, and has successfully completed a Phase 2a proof-of-concept study in adult volunteers.

RV521 best-in-class drug to treat RSV infections
  • RV521 is an oral antiviral with excellent drug-like characteristics
  • The compound is highly potent against multiple clinical strains of RSV
  • Highly potent against RSV in human vounteers 

RSV Medical Need

  • RSV is a major cause of respiratory infection in children, the immune-compromised and the elderly
  • There are no effective treatments or vaccines available against RSV
  • There is an unmet need for a safe and effective treatment with a simple route of administration
Meet the team...
Latest News
ReViral announces Series B investment

ReViral announces US$55 million series B fundraising to advance RSV clinical studies

London, UK – 1st August 2018:  ReViral, an antiviral...

Presentation at the American Thoracic Society

ReViral is pleased to announce that Professor John DeVincenzo from the Department of Pediatrics, University of Tennessee, Memphis, USA will be presenting at the American...

ReViral to present at American Chemical Society

ReViral's Chief Scientific Officer, Stuart Cockerill, will be presenting at the American Chemical Society in New Orleans. The afternoon session entitled "MEDI: First Time...

Contact us...